Sinclair Pharma Regulatory News (SPH)

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Sinclair Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify): Change to notifiable interest following share issue.

x

3. Full name of person(s) subject to thenotification obligation: iii

Abingworth LLP

Abingworth Bioventures V LP

Abingworth Bioequities Master Fund Limited

4. Full name of shareholder(s)  (if different from 3.):iv

State Street (Nominees) Limited (as nominee for Abingworth Bioventures V LP)

Jefferies & Co Inc. (as nominee for Abingworth Bioequities Master Fund Limited)

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

30 September 2016

6. Date on which issuer notified:

3 October 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

Downward crossing of 6% threshold - Abingworth LLP

8. Notified details: Abingworth LLP

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Sinclair Pharma plc

GB0033856740

1p Ords

33,433,227

29,674,270

5.91

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

29,674,270

5.91

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

Abingworth Bioventures V LP (which holds 22,573,542 shares in the company (4.50%)) and Abingworth Bioequities Master Fund Limited (which holds 7,100,728 shares in the company (1.41%)) are both managed by Abingworth LLP.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

John Heard

15. Contact telephone number:

0207 534 1500